Ramon Bosser possesses more than 25 years’ experience in the pharma and biotech industry, where he has gained extensive R&D, managerial and entrepreneurial skills. Previous to Agomab he was CEO of Origo Biopharma, and had been co-founder and COO at Spherium, a biotech company bringing projects from academia to clinical development in gastrointestinal, dermatology, pain,
Paolo is a growth factor expert and the CSO of Agomab. He spent several years conducting research at the National Cancer Institute, National Institutes of Health in Bethesda, Maryland, in the laboratory that discovered that MET is the HGF receptor in the early 1990s. Since he returned to Italy, he has been directing a translational
Reginald joined Agomab as head of research in February 2022. Prior to this role, Reginald was VP of drug discovery at Galapagos where he oversaw the company’s discovery portfolio, therapeutic area strategy in research and its translational research activities related to early development projects. Under his leadership, the company developed deep portfolios focused on immune-inflammatory,
Torsten is the CDO at Agomab and brings an extensive expertise in developing antibodies and antibody-based drugs with more than 20 years in the pharmaceutical industry. He has a successful track record of progressing 10 antibody products from preclinical research to clinical development, including two (Blincyto and Cablivi) that obtained marketing authorization. Prior to joining
Ellen joined Agomab as General Counsel in 2021. She previously served as Deputy General Counsel at Galapagos. In this role, she led the corporate law department and advised on all corporate development activities, including the company’s Nasdaq IPO and secondary offerings. Prior to this, she worked at corporate law firms Linklaters, Simpson, Thacher & Bartlett
Paul joined Agomab in 2021 as Chief Business Officer. Prior to Agomab, he was Head of Corporate Development at Galapagos from 2016-2021. In this role, he led all major transactions, investments, licensing and M&A activities for the company. Most notably, he was a key negotiator for Galapagos’ transformative $5bn strategic collaboration with Gilead Sciences. From
Andrea Sáez provides a strong scientific background complemented by broad experience in regulatory, biotech and venture capital roles. Previous to joining Agomab she was COO/CSO at Origo Biopharma. She initiated her academic career with a PhD in Immunology at the Pompeu Fabra University followed by a postdoctoral stay at Vall d’Hebron Hospital where she studied
Philippe joined Agomab as CMO in 2021. He was previously the CMO at Genkyotex where he led the company’s clinical development activities for the treatment of several fibrotic disorders in the liver, lung, and kidney. Prior to this role, Philippe co-founded Genexion, which was focused on developing early-stage clinical assets in partnership with emerging biotech
Tim is CEO and member of the Board of Directors of Agomab Therapeutics, a Belgian biotech company focusing on growth factor biology and developing therapeutics for fibrotic indications. Together with the team, he has raised $240 million and developed a broad pipeline since joining Agomab in 2019. Prior to Agomab, Tim held the position of
By continuing to use the site, you agree to the use of cookies. Privacy Policy
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Recent Comments